Rare Disease Report

The Energizer Bunny of Treatments - Daratumumab, Lenalidomide, and Dexamethasone

JANUARY 13, 2017
Saad Usmani, MD, FACP

Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about very impressive data showing the efficacy of daratumumab, lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma patients.


Usmani SZ, Dimopoulos M, Belch A,   et al. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux.Presented at the 58th Annual ASH Meeting & Exposition; San Diego, CA; December 3-6, 2016. Abstract 1151.

To stay informed about the latest in rare disease news, please sign up for our weekly newsletter at www.raredr.com/newsletter

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.